Evidence map›Paper›PMID 39041621›Full record

ArticleAIDS research and human retroviruses2025

IL-15/IL-15Ra Synergies with IL-12 to Induce Functional CD8 T Cells and NK Cells During Chronic SHIV Infection.

Sakthivel Govindaraj, Chris Ibegbu, Syed A Ali, Hemalatha Babu, Uma Shanmugasundaram, Francois Villinger, Rama Rao Amara, Vijayakumar Velu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS research and human retroviruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sakthivel GovindarajDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Chris IbegbuDivision of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Syed A AliNew Iberia Research Center, University of Louisiana at Lafayette, Lafayette, Louisiana, USA.
Hemalatha BabuDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Uma ShanmugasundaramDivision of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Francois VillingerNew Iberia Research Center, University of Louisiana at Lafayette, Lafayette, Louisiana, USA.
Rama Rao AmaraDivision of Microbiology and Immunology, Emory Vaccine Center, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Vijayakumar VeluDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0003-4238-1924

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Viral Testing Core-Maintenance of the SPF Breeding Colonies at Yerkes National Primate Research CenterU42OD011023 · OD · EMORY UNIVERSITY · PI Joyce Kimberly Cohen · 2018 to 2026
$17.5M
Preclinical Studies and T cell ResponsesU19AI109633 · NIAID · EMORY UNIVERSITY · PI VELU, VIJAYAKUMAR · 2014 to 2018
$10.2M
Combined cytokine therapy for sustained HIV remissionR01AI148377 · NIAID · EMORY UNIVERSITY · PI AMARA, RAMA RAO, VELU, VIJAYAKUMAR · 2020 to 2024
$4.6M
Blocking granzyme-mediated immune suppression to enhance HIV vaccine efficacyR01AI176519 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI Vijayakumar Velu, Stephen N. Waggoner · 2023 to 2026
$2.8M
IL-15 Therapy Combined with TGF-Beta Blockade for Sustained HIV RemissionR01AI187162 · NIAID · EMORY UNIVERSITY · PI ANTHONY T PODANY, Vijayakumar Velu · 2025 to 2026
$1.7M
NIAID NIH HHS R01 AI148377NIAID NIH HHS R01 AI176519NIAID NIH HHS R01 AI187162NIAID NIH HHS U19 AI109633NIH HHS P51 OD011132NIH HHS U42 OD011023
6 · The paper itself

Abstract

Cytokines are key mediators of immune regulation, orchestrate communication between immune cells, and play a pivotal role in shaping the immune landscape during chronic infection and cancer. The therapeutic potential of IL-15/IL-15Rα and IL-12 has been explored individually in various immunotherapeutic strategies, though not as a combination. Therefore, we investigated whether the combination of IL-15/IL-15Rα and IL-12 treatment would enhance the potency and quality of either NK cells, SIV-specific CD8 T cells, or both, compared with single cytokine treatment. Our findings reveal that

Indexed as

CD8-Positive T-LymphocytesInterleukin-12Interleukin-15Interleukin-15 Receptor alpha SubunitKiller Cells, NaturalSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsCD4-Positive T-LymphocytesMacaca mulattaInterleukin-12Interleukin-15Interleukin-15 Receptor alpha Subunitcytotoxic cellsIL-12IL-15/IL-15RaSHIV infection.

Identifiers

PMID39041621
PMCPMC11971607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.